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ORIGINAL ARTICLE
Hypoglycemia Prevention and User Acceptance
of an Insulin Pump System with Predictive
Low Glucose Management
Pratik Choudhary, MD,1 Birthe S. Olsen, MD,2 Ignacio Conget, MD,3
John B. Welsh, MD, PhD,4 Linda Vorrink, MSc,5 and John J. Shin, PhD4
Abstract
Background: The MiniMed 640G sensor-augmented insulin pump system (Medtronic, Inc., Northridge, CA)
can automatically suspend insulin delivery in advance of predicted hypoglycemia and restart it upon recovery.
The aims of this analysis were to determine the rate at which predicted hypoglycemia was avoided with this
strategy, as well as to assess user acceptance of the system and its insulin management features.
Subjects and Methods: Forty subjects with type 1 diabetes used the system for 4 weeks. We retrospectively
evaluated performance of the system, using downloaded pump and sensor data, and evaluated user acceptance
via questionnaires.
Results: There were 2,322 suspend before low events (2.1 per subject-day). The mean (– SD) duration of pump
suspension events was 56.4– 9.6min, and the mean subsequent sensor glucose (SG) nadir was 71.8– 5.2mg/dL.
SG values following 1,930 (83.1%) of the predictive suspensions did not reach the preset low limit. Nadir SG
values of £50 and £60mg/dL were seen in 207 (8.9%) and 356 (15.3%) of the predictive suspensions, re-
spectively. Blood glucose (BG) and SG values before and during the study were comparable (P > 0.05). The
mean absolute relative difference between paired SG and BG values was 10.9– 13.8%. Subjects felt confident
using the system, agreed that it helped protect them from hypoglycemia, and wished to continue using it.
Conclusions: Automatic insulin pump suspension as implemented in the MiniMed 640G system can help
patients avoid hypoglycemia, without significantly increasing hyperglycemia.
Introduction
In the context of sensor-augmented pump therapy,automatically suspending basal insulin delivery in response
to low sensor glucose (SG) levels is an established way to
reduce the severity and duration of hypoglycemic events.1–3
Suspending insulin delivery in response to predicted hypogly-
cemia has been tested in studies using various configurations of
pumps, sensors, induction protocols, and algorithms.4–6
The MiniMed 640G system (Medtronic, Inc., Northridge,
CA) includes a feature called SmartGuard, which includes a
predictive low glucose management algorithm, referred to as
suspend before low, that suspends insulin delivery when the
SG value is predicted to reach or fall below a preset low
glucose limit within 30min and automatically restarts basal
insulin on recovery from hypoglycemia. As of September
2015, the systemwas commercially available in the European
Union, Australia, Hong Kong, India, South Africa, Malaysia,
and Chile. Settings for suspend before low and programmable
alerts are customizable within multiple time blocks. Suspend
before low and automatic resumption of insulin delivery can
be programmed to occur with or without alerting the user. If
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the user-set low limit is reached, an alert that escalates will be
triggered. We conducted a user evaluation study to estimate
the system’s ability to prevent predicted hypoglycemia and its
acceptability to users and report our analysis here.
Research Design and Methods
Forty participants with type 1 diabetes (24 adults and 16
children) and prior experience with sensor-augmented pump
therapy were enrolled across three European sites after local
ethics committees’ approval. Following informed consent and
screening, patients were trained in use of the system, and
individualized targets were set up for the ‘‘low limit’’ between
50 and 80mg/dL (2.8–4.5mmol/L). Patients were trained by
investigators and staff members at each study site in a group
setting attended by Medtronic educators with the session
lasting 2–3 h. This included training on new pump features
and sensor use based on the ‘‘Getting Started Guide for
MiniMed 640G’’ document (available in English at https://
www.medtronic-diabetes.com.au/customer-support/guides-
and-manuals), as well as individualized settings for alerts
and threshold for the SmartGuard system based on discus-
sion between the clinicians and participants.
In addition to the pump, insulin reservoirs, and infusion
sets, subjects were provided with Bayer (Indianapolis, IN)
Contour Next Link 2.4 blood glucose (BG) meters and test
strips, New Generation Enlite sensors (Medtronic),7 and
Guardian 2 Link transmitters (Medtronic). They used the
system for 4 weeks, during which they had four phone con-
tacts. Pump and sensor data were collected at baseline and at
the end of study, and treatment satisfaction questionnaires
and free text comments were collected at the end of the study.
The SmartGuard system suspends insulin delivery if the
SG level is predicted to drop below 20mg/dL (1.1mmol/L)
above the preset low limit within the next 30min. Basal in-
sulin is automatically resumed once the SG value was at least
20mg/dL (1.1mmol/L) above the preset low limit and pre-
dicted to be at least 40mg/dL (2.2mmol/L) above it within
30min and insulin delivery has been suspended for at least
30min. The user can manually restart basal delivery at any
time, and basal insulin delivery is automatically resumed
after a maximum of 120min regardless of the SG level.
Suspend before low events were categorized according to
their duration (<30min, 30 to <90min, or ‡90min) and
starting time (daytime [08:00–22:00 h] or nighttime [22:00–
08:00 h]). Paired SG and BG values were used for accuracy
statistics. BG values used for calibrating the sensor were
excluded from accuracy calculations.
Results
Thirty-nine subjects completed the study; one subject
withdrew because of a devicemalfunction—an internal battery
failure that caused an alarmbut did not lead to an adverse event.
Subjects’ mean (– SD) age was 31.7– 17.1 years. Diabetes
duration was 17.2 – 13.3 years. Glycosylated hemoglobin
level was 7.6 – 0.9% (59.6– 9.5mmol/mol). Body mass in-
dex was 23.5– 4.0 kg//m2. Fifty-five percent were male.
The predictive low glucose management feature was used
for an average of 29.4 – 5.0 days. There were 2,322 suspend
before low events, a rate of 2.1 per subject per 24 h. The most
common time for any pump suspension event was in the early
afternoon, whereas the most common time for 2-h pump sus-
pension events was at night. The overall mean (– SD) duration
of a suspend before low event was 56.4–9.6min (median, 57.9
[interquartile range (IQR), 48.8–63.6] min). The mean duration
of daytime eventswas significantly shorter than that of nighttime
events (50.2–10.6 vs. 69.0–10.8min; P<0.0001). The mean
subsequent SG nadir was 71.8–5.2mg/dL (4.0–0.3mmol/L);
the median was 71.8 (IQR, 67.7–76.2) mg/dL (4.0 [3.8–4.2]
mmol/L). Nadir SG values of £60mg/dL (£3.3mmol/L) were
observed in 356 (15.3%) of the predictive suspensions, and of
these, the mean duration that SG values remained £60mg/dL
was 36.1– 23.6min, and the median (IQR) duration was 30
(20–45) min. Nadir SG values of £50mg/dL (£2.8mmol/L)
were observed in 207 (8.9%) of the predictive suspensions,
and of these, the mean duration that SG values remained
£50mg/dL was 25.3– 20.8min, and the median (IQR) du-
ration was 20 (10–35) min.
Figure 1A shows the trajectory of SG values surrounding
pump suspension events lasting <30, 30 to <90, and ‡90min,
normalized so that pump suspensions started at time 0. The
line at 54mg/dL (3.0mmol/L) shows the most commonly
used low limit value. In all of the 329 events lasting <30min,
insulin delivery was resumed manually. Of the 1,555 events
lasting 30 to <90min, insulin delivery was resumed manually
in 291 events (19%) and automatically in 1,264 events (81%).
Of the 438 events lasting ‡90min, insulin delivery was re-
sumed manually in 50 events (11%) and automatically in 388
events (89%).
Figure 1B shows the number of suspend before low events
according to starting time, as well as the proportion of those
that were followed by one or more SG values at or below the
preset threshold value. After 83.1% of the suspend before low
events, the SG value did not reach the preset low limit; this
rate was similar for events starting in the daytime and
nighttime hours.
Only 18 subjects had prestudy SG values available for
comparison with values collected during the study; 38 sub-
jects had prestudy BG values available for comparison. Mean
glucose values before and during the study were not signifi-
cantly different, whether obtained from the sensors (SG
values before and during, 158.9– 17.1 and 162.1– 20.9mg/
dL [8.8 – 1.0 and 9.0 – 1.2mmol/L], respectively; P > 0.05)
or the meters (BG values before and during, 176.9– 32.5 and
175.2– 25.9mg/dL [9.8– 1.8 and 9.7 – 1.4mmol/L], respec-
tively; P> 0.05). Of the 2,662 SG/BG paired points collected
during the study, the mean (– SD) absolute relative difference
(ARD) between them was 10.9 – 13.8%, and the median
ARD was 6.2%. Of the 274 paired points for which the BG
value was ‡60 and £90mg/dL, the mean (– SD) and median
ARD values were 15.1 – 13.5% and 12.2%, respectively.
Questionnaires estimated the extent of agreement or dis-
agreement with various statements using a 7-point scale
ranging from 1 (strong disagreement) to 7 (strong agreement).
All subjects felt confident using the suspend before low fea-
ture. Mean and median responses were between 6 and 7 for
‘‘The suspend by sensor features in this pump system provide
more protection from lows,’’ ‘‘I am able to better control my
glucose levelswith this system,’’ and ‘‘The suspend before low
feature helps protect against lows overnight.’’ Each of these
questions asked users to compare the MiniMed 640G system
with their previous pump system without those features. Ad-
ditional end-of-study results related to subjects’ use of and
preference for the system and its individual features are
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available in Supplementary Table S1 (Supplementary Data are
available online at www.liebertonline.com/dia). There was
one device malfunction but no device-related adverse events.
All four adverse events (one urinary tract infection, one case of
eczema under the sensor adhesive, one case of allergic reaction
to sensor overtape, and one common cold) were mild.
Discussion
These data suggest that the suspend before low feature of
SmartGuard, as implemented in the MiniMed 640G pump
system, is well tolerated and can prevent many hypoglycemic
events in patients with type 1 diabetes. Other system compo-
nents, including the New Generation Enlite sensors, performed
well. The high rate at which sensor-detected hypoglycemic
events were avoided is consistent with a previous study of the
algorithm in which hypoglycemia induced by insulin bolus
administration or exercise.8 A previous randomized controlled
trial of a similar system used at night9 showed that nocturnal
suspensions substantially reduced overnight hypoglycemia
without conferring an increased risk of morning ketosis, sug-
gesting that routine measurement of ketones is not necessary in
the context of automated pump suspension.10 A recent study of
the 640G algorithm implemented on a different hardware
configuration1 studied 10 patients in whom increased basal in-
sulin deliverywas intended to induce hypoglycemia; the authors
concluded that use of the algorithm had the potential to reduce
overnight hypoglycemia in patients on insulin pump therapy. In
contrast to these earlier studies, this is the first to evaluate the
commercially available system.
Routine use of the system was not associated with gly-
cemic deterioration as measured by prestudy and study phase
BG and SG values. The minimum automated suspend dura-
tion is 30min, so events terminated within 30min, as shown
FIG. 1. (A) Mean and SD of sensor glucose trajectories throughout suspend before low events lasting <30, 30 to <90, and
‡90min. The line at 54mg/dL (3.0mmol/L) represents the most commonly used threshold value. (B) Number and pro-
portion of nadir sensor glucose values following suspend before low events that were greater than the preset low limit
(white) or were at or below the preset low limit (black).
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by the dashed line in Figure 1A, were terminated early by the
user. These are followed by a faster and higher-amplitude rise
in glucose level, likely due to carbohydrate ingestion. In
contrast, the longest suspends (those lasting between 90 and
120min), shown with the continuous line, were frequently
terminated by the pump algorithm and were associated with a
more gradual recovery and less late hyperglycemia, possibly
due to automated resumption of insulin.
This was a short observational study, and the lack of a
control group prevents comparison of hypoglycemia pre-
vention rates that might have been obtained without predic-
tive pump suspension. The lack of a requirement for BG
confirmation of SG values surrounding pump suspension
events is a study limitation that precludes an estimate of the
system’s false-positive rate. The false-positive rate and the
duration of pump suspensions depend in part on sensor ac-
curacy in the low range, emphasizing the importance of
continued improvements in sensor design. However, the rate
of hypoglycemia, and in particular nocturnal hypoglycemia,
was low with this system, and there was a high degree of user
satisfaction recorded with the questionnaires. In particular,
the feeling of safety at night was commented on strongly. The
utility, feeling of nighttime security, and desire to continue
using the system reported by subjects in this user evaluation
study are similar to results from an earlier study of the Veo
system and its low glucose suspend feature.2 Carbohydrate
intake in response to symptomatic hypoglycemia was not
recorded, so its contribution to rebound hyperglycemia can-
not be determined, although in the comments section par-
ticipants reported a lower requirements for carbohydrate
intake in response to hypoglycemia.
In conclusion, the MiniMed 640G is the first commercially
available system with the ability to predictively suspend and
automatically restart basal insulin delivery based on contin-
uous glucose monitoring data. Automatic insulin pump sus-
pension with the predictive algorithm implemented in the
MiniMed 640G system can help patients avoid hypoglyce-
mia, without significantly increasing hyperglycemia. It is an
important step toward closed-loop systems and can be re-
commended for best practice routine care. The system’s long-
term impacts must be confirmed in further randomized con-
trolled studies and retrospective analyses.
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